NO992400L - Nye substituerte pyrazolderivater - Google Patents

Nye substituerte pyrazolderivater

Info

Publication number
NO992400L
NO992400L NO992400A NO992400A NO992400L NO 992400 L NO992400 L NO 992400L NO 992400 A NO992400 A NO 992400A NO 992400 A NO992400 A NO 992400A NO 992400 L NO992400 L NO 992400L
Authority
NO
Norway
Prior art keywords
pyrazole derivatives
substituted pyrazole
new substituted
medicaments
new
Prior art date
Application number
NO992400A
Other languages
English (en)
Norwegian (no)
Other versions
NO992400D0 (no
Inventor
Alexander Straub
Chantal Robyr
Thomas Jaetsch
Achim Feurer
Raimund Kast
Johannes-Peter Stasch
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO992400D0 publication Critical patent/NO992400D0/no
Publication of NO992400L publication Critical patent/NO992400L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO992400A 1996-11-26 1999-05-19 Nye substituerte pyrazolderivater NO992400L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19649460A DE19649460A1 (de) 1996-11-26 1996-11-26 Neue substituierte Pyrazolderivate
PCT/EP1997/006366 WO1998023619A1 (de) 1996-11-26 1997-11-14 Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen

Publications (2)

Publication Number Publication Date
NO992400D0 NO992400D0 (no) 1999-05-19
NO992400L true NO992400L (no) 1999-05-19

Family

ID=7813100

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992400A NO992400L (no) 1996-11-26 1999-05-19 Nye substituerte pyrazolderivater

Country Status (26)

Country Link
EP (1) EP0944631B1 (zh)
JP (2) JP4422800B2 (zh)
CN (1) CN1122032C (zh)
AR (1) AR010310A1 (zh)
AT (1) ATE259812T1 (zh)
AU (1) AU729642B2 (zh)
BR (1) BR9714363A (zh)
CA (1) CA2272584C (zh)
CZ (1) CZ185099A3 (zh)
DE (2) DE19649460A1 (zh)
DK (1) DK0944631T3 (zh)
EE (1) EE9900211A (zh)
ES (1) ES2214646T3 (zh)
HK (1) HK1023119A1 (zh)
HU (1) HUP0000562A3 (zh)
ID (1) ID21881A (zh)
IL (1) IL129998A0 (zh)
MX (1) MXPA99004826A (zh)
NO (1) NO992400L (zh)
NZ (1) NZ335890A (zh)
PT (1) PT944631E (zh)
SK (1) SK67699A3 (zh)
TR (1) TR199901172T2 (zh)
TW (1) TW403746B (zh)
WO (1) WO1998023619A1 (zh)
ZA (1) ZA9710573B (zh)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19827679A1 (de) * 1998-06-22 1999-12-23 Dresden Arzneimittel Adenosinrezeptoraffine, antikonvulsiv und antiallergisch/antiasthmatisch wirkende Pyrazolo[3,4-d]pyrimidine und Verfahren zu deren Herstellung
DE19834045A1 (de) * 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834047A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19920352A1 (de) * 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10021069A1 (de) * 2000-04-28 2001-10-31 Bayer Ag Substituiertes Pyrazolderivat
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
AU2002221827A1 (en) 2000-11-22 2002-06-03 Bayer Aktiengesellschaft Novel lactame-substituted pyrazolopyridine derivatives
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10057754A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
DE10109861A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate
DE10109858A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige halogensubstituierte Aminodicarbonsäurederivate
DE10110749A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10122894A1 (de) 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
DE10132416A1 (de) * 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10232572A1 (de) * 2002-07-18 2004-02-05 Bayer Ag Neue 2,5-disubstituierte Pyrimidinderivate
DE10244810A1 (de) 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
JP4499721B2 (ja) * 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102006020327A1 (de) * 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102007015034A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Lactam-substituierte Dicarbonsäuren und ihre Verwendung
DE102007015035A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Substituierte Dibenzoesäure-Derivate und ihre Verwendung
DE102007026392A1 (de) 2007-06-06 2008-12-11 Bayer Healthcare Ag Lösungen für die Perfusion und Konservierung von Organen und Geweben
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
RU2531354C2 (ru) 2008-04-28 2014-10-20 Янссен Фармацевтика Нв Бензоимидазолы как ингибиторы пролилгидроксилазы
EP2138178A1 (en) 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
AR088020A1 (es) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
CA2817319A1 (en) 2010-11-09 2012-05-18 Ironwood Pharmaceuticals, Inc. Triazole derivatives as sgc stimulators
CA2833698A1 (en) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Fluoroalkyl-substituted pyrazolopyridines and use thereof
SG11201400277VA (en) 2011-09-14 2014-05-29 Proximagen Ltd New enzyme inhibitor compounds
CN104066731B (zh) 2011-12-27 2016-06-15 铁木医药有限公司 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
CN104684932B (zh) 2012-05-10 2019-03-12 拜耳药业股份公司 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
TN2017000465A1 (en) 2015-05-06 2019-04-12 Bayer Pharma AG The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
WO2017013010A1 (de) 2015-07-23 2017-01-26 Bayer Pharma Aktiengesellschaft Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung
KR20180094965A (ko) 2015-12-14 2018-08-24 아이언우드 파마슈티컬스, 인코포레이티드 위장 괄약근 기능장애의 치료를 위한 sGC 자극제의 용도
WO2017121700A1 (de) * 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
US10918639B2 (en) 2016-10-11 2021-02-16 Bayer Pharma Aktiengesellschaft Combination containing SGC stimulators and mineralocorticoid receptor antagonists
CA3039735A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
EP3609883B1 (en) 2017-04-11 2022-06-29 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
EP3793553A1 (en) 2018-05-15 2021-03-24 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
JP7542518B2 (ja) 2018-07-11 2024-08-30 ティセント セラピューティクス インコーポレーテッド ミトコンドリア（ｍｉｔｏｃｈｏｎｒｉａｌ）障害の処置のためのｓＧＣ刺激剤の使用
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0615542B2 (ja) * 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US4994482A (en) * 1989-07-31 1991-02-19 Bristol-Myers Squibb Company Arylpyrazol derivatives as anti-platelet agents, compositions and use
WO1993023036A1 (en) * 1992-05-21 1993-11-25 Yoshitomi Pharmaceutical Industries, Ltd. Optically active condensed pyrazole compound for use in treating thrombocytopenia and erythropenia
JP2928079B2 (ja) * 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
CN1039536C (zh) * 1994-02-28 1998-08-19 永信药品工业股份有限公司 1,3取代缩合吡唑类化合物及其应用和制备方法

Also Published As

Publication number Publication date
HK1023119A1 (en) 2000-09-01
CZ185099A3 (cs) 1999-08-11
EE9900211A (et) 1999-12-15
WO1998023619A1 (de) 1998-06-04
PT944631E (pt) 2004-06-30
JP2001505567A (ja) 2001-04-24
AU5482398A (en) 1998-06-22
EP0944631A1 (de) 1999-09-29
SK67699A3 (en) 2000-02-14
ZA9710573B (en) 1998-06-10
BR9714363A (pt) 2000-03-21
HUP0000562A2 (hu) 2000-10-28
NZ335890A (en) 2001-02-23
JP2010013475A (ja) 2010-01-21
DE59711321D1 (de) 2004-03-25
CN1122032C (zh) 2003-09-24
AR010310A1 (es) 2000-06-07
ATE259812T1 (de) 2004-03-15
TW403746B (en) 2000-09-01
NO992400D0 (no) 1999-05-19
IL129998A0 (en) 2000-02-29
AU729642B2 (en) 2001-02-08
CN1238773A (zh) 1999-12-15
CA2272584C (en) 2007-10-16
JP4422800B2 (ja) 2010-02-24
DE19649460A1 (de) 1998-05-28
ES2214646T3 (es) 2004-09-16
TR199901172T2 (xx) 1999-08-23
HUP0000562A3 (en) 2001-12-28
MXPA99004826A (es) 2008-02-19
CA2272584A1 (en) 1998-06-04
DK0944631T3 (da) 2004-06-07
EP0944631B1 (de) 2004-02-18
ID21881A (id) 1999-08-05

Similar Documents

Publication Publication Date Title
NO992400L (no) Nye substituerte pyrazolderivater
NO991732L (no) Nye heterocyklylmetylsubstituerte pyrazolderivater
MY133392A (en) Novel substituted pyrazole derivatives
NO20030374D0 (no) Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
NO20075065L (no) Anvendelse av isoflavonforbindelser til a behandle hjertesykdom
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
IS4226A (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
NO20006645L (no) Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme
EA200100958A1 (ru) Производные 4,5-диарил-3(2h)-фуранона как ингибиторы циклооксигеназы-2
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
TR199700956T1 (xx) Indazolkarboksamidler.
NO995431D0 (no) Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse
TR200100637T2 (tr) Yeni doğal ürün türevleri
NO983860L (no) Nye triazolopuriner, fremgangsmÕte for deres fremstilling og deres anvendelse som legemidler
NO970573L (no) Ylidenforbindelser og deres fremstilling
ATE322244T1 (de) Verwendung von polyaminosäurederivaten zur behandlung von seborrhoe und verwandten hautstörungen
TR200400907T4 (tr) Beta D 5-Tiyoksiloz türevleri, bunları hazırlama yöntemi ve bunların terapötik kullanımları
NO991589L (no) Nye 3-,5- og/eller 6-substituerte analoger av swainsonin, fremgangsmÕter for deres fremstilling og deres anvendelse som terapeutiske midler
HUP9801925A1 (hu) Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
NO20020308D0 (no) Fremgangsmåte for fremstilling av epothiolon B og derivater, såvel som mellomprodukter for fremgangsmåten
TR199901385T2 (xx) Piperidin t�revleri.
CO5150221A1 (es) Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas